Cargando…

M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY

BACKGROUND: The dopamine system is a central focus of research on the pathophysiology and treatment of schizophrenia. With regard to the dopamine D2-receptor (D2-R), Positron Emission Tomography (PET) studies have shown a small increase in striatal receptor availability. In contrast, a more recent l...

Descripción completa

Detalles Bibliográficos
Autores principales: Victorsson, Pauliina, Plavén-Sigray, Pontus, Matheson, Granville, Santillo, Alexander, Lee, Maria, Collste, Karin, Fatouros-Bergman, Helena, Agartz, Ingrid, Halldin, Christer, Farde, Lars, Cervenka, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233970/
http://dx.doi.org/10.1093/schbul/sbaa030.319
_version_ 1783535655943405568
author Victorsson, Pauliina
Plavén-Sigray, Pontus
Matheson, Granville
Santillo, Alexander
Lee, Maria
Collste, Karin
Fatouros-Bergman, Helena
Agartz, Ingrid
Halldin, Christer
Farde, Lars
Cervenka, Simon
author_facet Victorsson, Pauliina
Plavén-Sigray, Pontus
Matheson, Granville
Santillo, Alexander
Lee, Maria
Collste, Karin
Fatouros-Bergman, Helena
Agartz, Ingrid
Halldin, Christer
Farde, Lars
Cervenka, Simon
author_sort Victorsson, Pauliina
collection PubMed
description BACKGROUND: The dopamine system is a central focus of research on the pathophysiology and treatment of schizophrenia. With regard to the dopamine D2-receptor (D2-R), Positron Emission Tomography (PET) studies have shown a small increase in striatal receptor availability. In contrast, a more recent line of research has demonstrated lower levels of D2-R (Cohen’s D = -0.32) in the thalamus, a region of key interest for the pathophysiology of schizophrenia. However, some studies included patients previously on antipsychotic medication, or were performed using radioligands with suboptimal affinity for the much lower D2-R density in thalamus compared to striatum. In addition, the resolution of previous PET systems has not allowed for a more detailed analysis of functional thalamic subregions. Here we examined a fully antipsychotic-naïve sample of first-episode psychosis patients using the high-affinity D2-R radioligand [11C]FLB457 and high-resolution PET. The aim was to a) replicate previous findings of lower D2-R in thalamus in patients and b) specifically examine patient-control differences in thalamic subregions based on their cortical connectivity. METHODS: Nineteen antipsychotic-naïve first episode psychosis patients (mean age = 29.3; sd = 6.3, 11 males) and 19 age- and sex matched healthy comparison subjects were included in the analysis. PET measurements were obtained using a High Resolution Research Tomograph (HRRT). A ROI for whole thalamus was defined using the FSL Harvard Oxford Subcortical Atlas, whereas ROIs for thalamic subregions were based on the Oxford Thalamic Connectivity Atlas. Binding potential (BPND) was calculated using the Logan graphical analysis with cerebellum as reference region. The statistical analyses, which were all pre-registered, were performed using frequentist and Bayesian paired-samples t-tests. RESULTS: The frequentist paired t-test showed that patients had significantly lower binding than control subjects in whole thalamus (Cohen’s D = -0.479, p = 0.026). Bayes factor from the Bayesian paired t-test indicated that there was approximately 5 times more support for the hypothesis of lower BPND in patients, compared to the null hypothesis of no difference. Among subregions, the ROI corresponding to prefrontal thalamic connectivity showed the largest effect (Cohen’s D = -0.527, p = 0.017), and Bayes factor indicated that there was 6 times more support for lower BPND in patients compared to no difference. DISCUSSION: Using high resolution PET and a high affinity D2-R radioligand in antipsychotic-naïve first-episode psychosis patients, this study replicates the previously reported meta-analytical effect size of lower thalamic receptor availability in patients. The strongest effect was observed in the subregion dominated by connections to prefrontal cortex. The findings may reflect a dysregulation of the thalamic dopamine system in schizophrenia, which in turn could underlie aberrant functional connectivity in key fronto-thalamic circuits.
format Online
Article
Text
id pubmed-7233970
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72339702020-05-23 M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY Victorsson, Pauliina Plavén-Sigray, Pontus Matheson, Granville Santillo, Alexander Lee, Maria Collste, Karin Fatouros-Bergman, Helena Agartz, Ingrid Halldin, Christer Farde, Lars Cervenka, Simon Schizophr Bull Poster Session II BACKGROUND: The dopamine system is a central focus of research on the pathophysiology and treatment of schizophrenia. With regard to the dopamine D2-receptor (D2-R), Positron Emission Tomography (PET) studies have shown a small increase in striatal receptor availability. In contrast, a more recent line of research has demonstrated lower levels of D2-R (Cohen’s D = -0.32) in the thalamus, a region of key interest for the pathophysiology of schizophrenia. However, some studies included patients previously on antipsychotic medication, or were performed using radioligands with suboptimal affinity for the much lower D2-R density in thalamus compared to striatum. In addition, the resolution of previous PET systems has not allowed for a more detailed analysis of functional thalamic subregions. Here we examined a fully antipsychotic-naïve sample of first-episode psychosis patients using the high-affinity D2-R radioligand [11C]FLB457 and high-resolution PET. The aim was to a) replicate previous findings of lower D2-R in thalamus in patients and b) specifically examine patient-control differences in thalamic subregions based on their cortical connectivity. METHODS: Nineteen antipsychotic-naïve first episode psychosis patients (mean age = 29.3; sd = 6.3, 11 males) and 19 age- and sex matched healthy comparison subjects were included in the analysis. PET measurements were obtained using a High Resolution Research Tomograph (HRRT). A ROI for whole thalamus was defined using the FSL Harvard Oxford Subcortical Atlas, whereas ROIs for thalamic subregions were based on the Oxford Thalamic Connectivity Atlas. Binding potential (BPND) was calculated using the Logan graphical analysis with cerebellum as reference region. The statistical analyses, which were all pre-registered, were performed using frequentist and Bayesian paired-samples t-tests. RESULTS: The frequentist paired t-test showed that patients had significantly lower binding than control subjects in whole thalamus (Cohen’s D = -0.479, p = 0.026). Bayes factor from the Bayesian paired t-test indicated that there was approximately 5 times more support for the hypothesis of lower BPND in patients, compared to the null hypothesis of no difference. Among subregions, the ROI corresponding to prefrontal thalamic connectivity showed the largest effect (Cohen’s D = -0.527, p = 0.017), and Bayes factor indicated that there was 6 times more support for lower BPND in patients compared to no difference. DISCUSSION: Using high resolution PET and a high affinity D2-R radioligand in antipsychotic-naïve first-episode psychosis patients, this study replicates the previously reported meta-analytical effect size of lower thalamic receptor availability in patients. The strongest effect was observed in the subregion dominated by connections to prefrontal cortex. The findings may reflect a dysregulation of the thalamic dopamine system in schizophrenia, which in turn could underlie aberrant functional connectivity in key fronto-thalamic circuits. Oxford University Press 2020-05 2020-05-18 /pmc/articles/PMC7233970/ http://dx.doi.org/10.1093/schbul/sbaa030.319 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Session II
Victorsson, Pauliina
Plavén-Sigray, Pontus
Matheson, Granville
Santillo, Alexander
Lee, Maria
Collste, Karin
Fatouros-Bergman, Helena
Agartz, Ingrid
Halldin, Christer
Farde, Lars
Cervenka, Simon
M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY
title M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY
title_full M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY
title_fullStr M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY
title_full_unstemmed M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY
title_short M7. LOWER THALAMIC DOPAMINE D2-RECEPTOR BINDING IN DRUG-NAIVE PATIENTS WITH PSYCHOSIS – A REPLICATION STUDY USING POSITRON EMISSION TOMOGRAPHY
title_sort m7. lower thalamic dopamine d2-receptor binding in drug-naive patients with psychosis – a replication study using positron emission tomography
topic Poster Session II
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233970/
http://dx.doi.org/10.1093/schbul/sbaa030.319
work_keys_str_mv AT victorssonpauliina m7lowerthalamicdopamined2receptorbindingindrugnaivepatientswithpsychosisareplicationstudyusingpositronemissiontomography
AT plavensigraypontus m7lowerthalamicdopamined2receptorbindingindrugnaivepatientswithpsychosisareplicationstudyusingpositronemissiontomography
AT mathesongranville m7lowerthalamicdopamined2receptorbindingindrugnaivepatientswithpsychosisareplicationstudyusingpositronemissiontomography
AT santilloalexander m7lowerthalamicdopamined2receptorbindingindrugnaivepatientswithpsychosisareplicationstudyusingpositronemissiontomography
AT leemaria m7lowerthalamicdopamined2receptorbindingindrugnaivepatientswithpsychosisareplicationstudyusingpositronemissiontomography
AT collstekarin m7lowerthalamicdopamined2receptorbindingindrugnaivepatientswithpsychosisareplicationstudyusingpositronemissiontomography
AT fatourosbergmanhelena m7lowerthalamicdopamined2receptorbindingindrugnaivepatientswithpsychosisareplicationstudyusingpositronemissiontomography
AT agartzingrid m7lowerthalamicdopamined2receptorbindingindrugnaivepatientswithpsychosisareplicationstudyusingpositronemissiontomography
AT halldinchrister m7lowerthalamicdopamined2receptorbindingindrugnaivepatientswithpsychosisareplicationstudyusingpositronemissiontomography
AT fardelars m7lowerthalamicdopamined2receptorbindingindrugnaivepatientswithpsychosisareplicationstudyusingpositronemissiontomography
AT cervenkasimon m7lowerthalamicdopamined2receptorbindingindrugnaivepatientswithpsychosisareplicationstudyusingpositronemissiontomography